Safinamide for the treatment of Parkinson's disease

Bibliography

• Olanow CW, Stern MB, Sethi C. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009;72:S1-S136
   PubMed Web of Science ®Google Scholar
• Olanow CW. Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. Neurology 2006;66:S69-79
   PubMed Web of Science ®Google Scholar
• Kincses ZT, Vécsei L. Pharmacological therapy in Parkinson's disease: focus on neuroprotection. CNS Neurosci Ther 2010;17:345-67
   PubMed Web of Science ®Google Scholar
• Zádori D, Szalárdy L, Toldi J, et al. Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease. J Neural Transm 2013;120:673-81
   PubMed Web of Science ®Google Scholar
• Müller T. Drug therapy in patients with Parkinson's disease. Translational Neurodeg 2012;1:10
   PubMedGoogle Scholar
• Klivényi P, Vécsei L. Novel therapeutic strategies in Parkinson's disease. Eur J Clin Pharmacol 2010;66:119-25
   PubMed Web of Science ®Google Scholar
• Smith Y, Wichmann T, Factor SA, et al. Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacol Rev 2012;37:213-46
   PubMed Web of Science ®Google Scholar
• Wright BA, Waters CH. Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease. Expert Rev Neurother 2013;13:719-29
   PubMed Web of Science ®Google Scholar
• Poewe W, Antonini A, Zijlmans JCM, et al. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging 2010;5:229-38
   PubMed Web of Science ®Google Scholar
• Hauser RA, Panisset M, Abbruzzese G, et al. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord 2009;24:541-50
   PubMed Web of Science ®Google Scholar
• Abbruzzese G, Barone P, Bonucelli U, et al. Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection. Funct Neurol 2012;27:147-54
   PubMed Web of Science ®Google Scholar
• Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained release tablets. Clin Neuropharmacol 2003;26:156-63
   PubMed Web of Science ®Google Scholar
• Stocchi F. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease. Parkinsonism Relat Disord 2009;15:S9-S15
   PubMed Web of Science ®Google Scholar
• Nutt JG. Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa? Mov Disord 2007;22:1-9
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Odin P. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. Curr Med Res Opin 2011;27:907-19
   PubMed Web of Science ®Google Scholar
• Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8:657-64
   PubMed Web of Science ®Google Scholar
• Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007;22:1145-9
   PubMed Web of Science ®Google Scholar
• Eggert K, Schrader C, Hahn M, et al. Continuous jejunal levodopa infusion in patients with advanced Parkinson's disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31:151-66
   PubMed Web of Science ®Google Scholar
• Antonini A, Bondiolotti G, Natuzzi F, et al. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa. Eur Neuropsychopharmacol 2010;20:683-7
   PubMed Web of Science ®Google Scholar
• Puente V, De Fabregues O, Oliveras C, et al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord 2010;16:218-21
   PubMed Web of Science ®Google Scholar
• Merola A, Zibetti M, Angrisano S, et al. Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease. Mov Disord 2011;26:664-70
   PubMed Web of Science ®Google Scholar
• Devos D, French Duodopa Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009;24:993-1000
   PubMed Web of Science ®Google Scholar
• Nyholm D, Lewander T, Johansson A, et al. Enteral levodopa/carbidopa infusion in advanced Parkinson's disease: long-term exposure. Clin Neuropharmacol 2008;31:63-73
   PubMed Web of Science ®Google Scholar
• Politis M, Piccini P, Pavese N, et al. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride study. Exp Neurol 2008;214:112-16
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-74
   PubMed Web of Science ®Google Scholar
• Witjas T, Kaphan E, Azulay JP. Non-motor fluctuations in Parkinson's disease. Rev Neurol 2007;163:846-50
   PubMedGoogle Scholar
• Hauser DN, Hastings TG. Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol Dis 2013;51:35-42
   PubMed Web of Science ®Google Scholar
• Knoll J, Ecsery Z, Magyar K, et al. Novel (-)deprenyl-derived selective inhibitors of B-type monoamine oxidase. The relation of structure to their action. Biochem Pharmacol 1978;27:1739-47
   PubMed Web of Science ®Google Scholar
• Tábi T, Szökő É, Vecsei L, et al. The pharmacokinetic evaluation of selegiline (ODT) for the treatment of Parkinson's disease. Expert Opin Drug Metab Toxicol 2013;9:699-712
   PubMed Web of Science ®Google Scholar
• Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996;47(Suppl 3):S161-70
   PubMed Web of Science ®Google Scholar
• Riederer P, Lachenmayer L, Laux G. Clinical applications of MAO-inhibitors. Curr Med Chem 2004;11:2033-43
   PubMed Web of Science ®Google Scholar
• Müller T, Przuntek H, Rieks M, et al. Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells. Neurol Res 2008;30:417-19
   PubMed Web of Science ®Google Scholar
• Bartl J, Müller T, Grünblatt E, et al. Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. J Neural Transm 2013, doi:10.1007/s00702-013-1120-z
   Web of Science ®Google Scholar
• Palhagen S, Heinonen E, Hagglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006;66:1200-6
   PubMed Web of Science ®Google Scholar
• Hauser RA, Lew MF, Hurtig HI, et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 2009;24:564-73
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease, the TEMPO study. Arch Neurol 2002;59:1937-43
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson's disease. Arch Neurol 2004;61:561-6
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations, the PRESTO study. Arch Neurol 2005;62:241-8
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel group trial. Lancet 2005;365:947-54
   PubMed Web of Science ®Google Scholar
• Giladi N, Rascol O, Brooks DJ, et al. Rasagiline treatment can improve freezing of gait in advanced Parkinson's disease; a prospective randomized, double-blind, placebo and entacapone controlled study. Neurology 2004;62(Suppl 5):329-30
   Google Scholar
• Poewe W, Hauser R, Lang AE. Rasagiline 1 mg/day provides benefits in the progression of non-motor symptoms in patients with early Parkinson's disease: assessment with the revised MDS-UPDRS. Mov Disord 2009;24(Suppl 1):S272
   Google Scholar
• Minguez-Minguez S, Solis-Garcia del Pozo J, Jordan J. Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data. Pharmacol Res 2013;74:78-86
   PubMed Web of Science ®Google Scholar
• van Dorsser W, Barris D, Cordi A, et al. Anticonvulsant activity of milacemide. Arch Int Pharmacodyn Ther 1983;266:239-49
   PubMedGoogle Scholar
• Colombo M, Strolin Benedetti M, et al. MAO activity, metabolism and anticonvulsant activity of milacemide in rats and mice. J Neural Transm Suppl 1990;32:123-9
   PubMedGoogle Scholar
• Pevarello P, Bonsignori A, Dostert P, et al. Synthesis and anticonvulsant activity of a new class of 2-[(arylalkyl)amino]alkanamide derivatives. J Med Chem 1998;41:579-90
   PubMed Web of Science ®Google Scholar
• Chazot PL. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. Curr Opin Investig Drugs 2007;8:570-9
   PubMed Web of Science ®Google Scholar
• Caccia C, Maj R, Calabresi M, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 2006;67:S18-23
   PubMed Web of Science ®Google Scholar
• De Leonibus E, Manago F, Giordani F, et al. Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease. Neuropsychopharmacology 2009;34:729-38
   PubMed Web of Science ®Google Scholar
• Müller T. Current status of safinamide for the drug portofolio of Parkinson's disease therapy. Expert Rev neurother 2013;13:969-77
   PubMed Web of Science ®Google Scholar
• Marzo A, Dal Bo L, Monti NC, et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res 2004;50:77-85
   PubMed Web of Science ®Google Scholar
• Leuratti C, Sardina M, Ventura P, et al. Disposition and metabolism of safinamide, a novel drug fro Parkinson's disease, in healthy male volunteers. Pharmacology 2013;92:207-16
   PubMed Web of Science ®Google Scholar
• Onofrj M, Bonanni L, Thomas A. An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs 2008;17:1115-25
   PubMed Web of Science ®Google Scholar
• Krössner S, Marquet A, Gallemann D, et al. Effects of ketokonazole treatment on the pharmacokynetics of safinamide ant its plasma metabolites in healthy adult subjects. Biopharm Drug Dispos 2012;33:550-9
   PubMed Web of Science ®Google Scholar
• Seithel-Keuth A, Johne A, Freisleben A, et al. Absolute bioavailability and effect of food on the disposition of safinamide immediate release tablets in healthy adult subjects. J Clin Pharmacol Drug Dev 2013;2:79-89
   PubMed Web of Science ®Google Scholar
• NW 1015 antiepileptic compound, Investigator's Brochure, Newron Pharmaceuticals, October 21, 1999
   Google Scholar
• Cattaneo C, Caccia C, Marzo A, et al. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. Clin Neuropharmacol 2003;26:213-17
   PubMed Web of Science ®Google Scholar
• Caccia C, Salvati P, Rossetti S, et al. Safinamide beyond MAO-B inhibition. Parkinsonism Relat Disord 2007;13(Suppl 2):S99
   Google Scholar
• Fariello RG. Safinamide. Neurotherapeutics 2007;4:110-16
   PubMed Web of Science ®Google Scholar
• Schapira AH. Safinamide in the treatment of Parkinson's disease. Expert Opin Pharmacother 2010;11:2261-8
   PubMed Web of Science ®Google Scholar
• Stocchi F, Borgohain R, Onofrj M, et al. A randomized double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov Disord 2012;27:106-12
   PubMed Web of Science ®Google Scholar
• Binda C, Hubalek F, Li M, et al. Structure of the human mitochondrial monoamine oxidase B: new chemical implications for neuroprotectant drug design. Neurology 2006;67(Suppl 2):S5-7
   PubMedGoogle Scholar
• Salvati P, Maj R, Caccia C, et al. Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound. J Pharmacol Exp Ther 1999;288:1151-9
   PubMed Web of Science ®Google Scholar
• Caccia C, Salvati P, Rossetti S, et al. Safinamide: modulation of dopaminergic and glutamatergic systems. Mov Disord 2008;23:S22-3
   Web of Science ®Google Scholar
• Binda C, Wang J, Pisani L, et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 2007;50:5848-52
   PubMed Web of Science ®Google Scholar
• Stocchi F, Vacca L, Grassini P, et al. Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology 2006;67(Suppl 2):S24-9
   PubMedGoogle Scholar
• Kupsch A, Sautter J, Götz ME, et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm 2001;108:985-1009
   PubMed Web of Science ®Google Scholar
• Grégoire L, Jourdain VA, Townsend M, et al. Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord 2013;19:508-14
   PubMed Web of Science ®Google Scholar
• Podurgiel S, Collins-Praino LE, Yohn S, et al. Tremorolytic effect of safinamide in animal models of drug-induced parkinsonian tremor. Pharmacol Biochem Behav 2013;105:105-11
   PubMed Web of Science ®Google Scholar
• Stocchi F, Arnold G, Onofrj M, et al. Safinamide Parkinson's Study Group: improvement of motor function in early Parkinson disease by safinamide. Neurology 2004;24:746-8
   Google Scholar
• Schapira AH. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease. CNS Drugs 2011;25:1061-71
   PubMed Web of Science ®Google Scholar
• Schapira AH, Stocchi F, Borgohain R, et al. Long term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. Eur J Neurol 2013;20:271-80
   PubMed Web of Science ®Google Scholar
• Available from: http://www.clinicaltrials.gov/ct2/show/NCT00605683?term=27918&rank=2
   Google Scholar
• Available from: http://www.clinicaltrials.gov/ct2/show/NCT01028586?term=27918&rank=1
   Google Scholar
• Hauser RA, Silver D, Choudhry A, Isaacson S. A placebo controlled, randomized, double-blind study to assess the safety and clinical benefit of rasagiline as an add-on to dopamine agonist monotherapy in early Parkinson's disease (PD): the ANDANTE study [abstract]. Movement Disord 2013;28(Suppl 1):446
   Google Scholar
• Available from: http://clinicaltrials.gov/show/NCT01113320
   Google Scholar
• First long-term (2-year) controlled study to evaluate treatment with safinamide as add-on to levodopa in patients with Parkinson's disease and motor fluctuations. American Academy of Neurology annual meeting; 9 – 16 April 2011; Honolulu, Hawaii, USA; P05287
   Google Scholar
• Borgohain R, Szasz J, Stanzione P. First 2-year, controlled study to assess safinamide as add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord 2011;26(Suppl 2):S120
   Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord 2013, doi:10.1002/mds.25751
   PubMed Web of Science ®Google Scholar
• Bargiotas P, Konitsiotis S. Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments. Neuropsychiatr Dis Treat 2013;9:1605-17
   PubMed Web of Science ®Google Scholar
• Fox SH. Non-dopaminergic treatments for motor control in Parkinson's disease. Drugs 2013;73:1405-15
   PubMed Web of Science ®Google Scholar
• Schapira AH, Fox S, Hauser R, et al. Safinamide add on to L-dopa: a randomized, placebo-controlled 24-week global trial in patients with Parkinson's disease and motor fluctuations (SETTLE) [poster 1062]. Abstract 65th Annual American Academy of Neurology, San Diego; 2013
   Google Scholar
• Available from: http://www.clinicaltrials.gov/ct2/show/NCT00865579?term=safinamide+Parkinson&rank=3
   Google Scholar
• Available from: http://www.clinicaltrials.gov/ct2/show/NCT01211587?term=safinamide+Parkinson&rank=2
   Google Scholar
• Available from: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=401196
   Google Scholar
• Vámos E, Párdutz A, Klivenyi P, et al. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection. J Neurol Sci 2009;283:21-7
   PubMed Web of Science ®Google Scholar
• Zádori D, Klivényi P, Vamos E, et al. Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. J Neural Transm 2009;116:1403-9
   PubMed Web of Science ®Google Scholar
• Németh H, Toldi J, Vécsei L. Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. J Neurol Transm Suppl 2006;70:285-304
   PubMedGoogle Scholar
• Vécsei L, Szalárdy L, Fülöp F, et al. Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 2013;12:64-82
   PubMed Web of Science ®Google Scholar
• Zádori D, Klivényi P, Toldi J. Kynurenines in Parkinson's disease: therapeutic perspectives. J Neural Transm 2012;119:275-83
   PubMed Web of Science ®Google Scholar
• Szabó N, Kincses ZT, Toldi J, et al. Altered tryptophan metabolism in Parkinson's disease: a possible novel therapeutic approach. J Neurol Sci 2011;310:256-60
   PubMed Web of Science ®Google Scholar